Table of Contents

1 Study Coverage

• 1.1 Dermatophytosis Drugs Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Dermatophytosis Drugs Market Size Growth Rate by Product
  • 1.4.2 Rx
  • 1.4.3 OTC
• 1.5 Market by End User
  • 1.5.1 Global Dermatophytosis Drugs Market Size Growth Rate by End User
  • 1.5.2 Hospital
  • 1.5.3 Clinic
  • 1.5.4 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Dermatophytosis Drugs Market Size
  • 2.1.1 Global Dermatophytosis Drugs Revenue 2014-2025
  • 2.1.2 Global Dermatophytosis Drugs Sales 2014-2025
• 2.2 Dermatophytosis Drugs Growth Rate by Regions
  • 2.2.1 Global Dermatophytosis Drugs Sales by Regions
  • 2.2.2 Global Dermatophytosis Drugs Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Dermatophytosis Drugs Sales by Manufacturers
  • 3.1.1 Dermatophytosis Drugs Sales by Manufacturers
  • 3.1.2 Dermatophytosis Drugs Sales Market Share by Manufacturers
  • 3.1.3 Global Dermatophytosis Drugs Market Concentration Ratio (CR5 and HHI)
• 3.2 Dermatophytosis Drugs Revenue by Manufacturers
  • 3.2.1 Dermatophytosis Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Dermatophytosis Drugs Revenue Share by Manufacturers (2014-2019)
• 3.3 Dermatophytosis Drugs Price by Manufacturers
• 3.4 Dermatophytosis Drugs Manufacturing Base Distribution, Product Types
  • 3.4.1 Dermatophytosis Drugs Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Dermatophytosis Drugs Product Type
  • 3.4.3 Date of International Manufacturers Enter into Dermatophytosis Drugs Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Dermatophytosis Drugs Sales by Product
• 4.2 Global Dermatophytosis Drugs Revenue by Product
• 4.3 Dermatophytosis Drugs Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Dermatophytosis Drugs Breakdown Data by End User

6 North America

• 6.1 North America Dermatophytosis Drugs by Countries
  • 6.1.1 North America Dermatophytosis Drugs Sales by Countries
  • 6.1.2 North America Dermatophytosis Drugs Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Dermatophytosis Drugs by Product
• 6.3 North America Dermatophytosis Drugs by End User

7 Europe

• 7.1 Europe Dermatophytosis Drugs by Countries
  • 7.1.1 Europe Dermatophytosis Drugs Sales by Countries
  • 7.1.2 Europe Dermatophytosis Drugs Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Dermatophytosis Drugs by Product
• 7.3 Europe Dermatophytosis Drugs by End User

8 Asia Pacific

• 8.1 Asia Pacific Dermatophytosis Drugs by Countries
  • 8.1.1 Asia Pacific Dermatophytosis Drugs Sales by Countries
  • 8.1.2 Asia Pacific Dermatophytosis Drugs Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Dermatophytosis Drugs by Product
• 8.3 Asia Pacific Dermatophytosis Drugs by End User

9 Central & South America

• 9.1 Central & South America Dermatophytosis Drugs by Countries
  • 9.1.1 Central & South America Dermatophytosis Drugs Sales by Countries
  • 9.1.2 Central & South America Dermatophytosis Drugs Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Dermatophytosis Drugs by Product
• 9.3 Central & South America Dermatophytosis Drugs by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Dermatophytosis Drugs by Countries
  • 10.1.1 Middle East and Africa Dermatophytosis Drugs Sales by Countries
  • 10.1.2 Middle East and Africa Dermatophytosis Drugs Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Dermatophytosis Drugs by Product
• 10.3 Middle East and Africa Dermatophytosis Drugs by End User

11 Company Profiles

• 11.1 Novartis
  • 11.1.1 Novartis Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Novartis Dermatophytosis Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Novartis Dermatophytosis Drugs Products Offered
  • 11.1.5 Novartis Recent Development
• 11.2 Pfizer
  • 11.2.1 Pfizer Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Pfizer Dermatophytosis Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Pfizer Dermatophytosis Drugs Products Offered
  • 11.2.5 Pfizer Recent Development
• 11.3 Sanofi-Aventis
  • 11.3.1 Sanofi-Aventis Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Sanofi-Aventis Dermatophytosis Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Sanofi-Aventis Dermatophytosis Drugs Products Offered
  • 11.3.5 Sanofi-Aventis Recent Development
• 11.4 Merck
  • 11.4.1 Merck Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Merck Dermatophytosis Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Merck Dermatophytosis Drugs Products Offered
  • 11.4.5 Merck Recent Development
• 11.5 Enzon Pharmaceuticals
  • 11.5.1 Enzon Pharmaceuticals Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Enzon Pharmaceuticals Dermatophytosis Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Enzon Pharmaceuticals Dermatophytosis Drugs Products Offered
  • 11.5.5 Enzon Pharmaceuticals Recent Development
• 11.6 Bayer
  • 11.6.1 Bayer Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Bayer Dermatophytosis Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Bayer Dermatophytosis Drugs Products Offered
  • 11.6.5 Bayer Recent Development
• 11.7 Astellas Pharma
  • 11.7.1 Astellas Pharma Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Astellas Pharma Dermatophytosis Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Astellas Pharma Dermatophytosis Drugs Products Offered
  • 11.7.5 Astellas Pharma Recent Development
• 11.8 GSK
  • 11.8.1 GSK Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 GSK Dermatophytosis Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 GSK Dermatophytosis Drugs Products Offered
  • 11.8.5 GSK Recent Development
• 11.9 Abbott
  • 11.9.1 Abbott Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Abbott Dermatophytosis Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Abbott Dermatophytosis Drugs Products Offered
  • 11.9.5 Abbott Recent Development

12 Future Forecast

• 12.1 Dermatophytosis Drugs Market Forecast by Regions
  • 12.1.1 Global Dermatophytosis Drugs Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Dermatophytosis Drugs Revenue Forecast by Regions 2019-2025
• 12.2 Dermatophytosis Drugs Market Forecast by Product
  • 12.2.1 Global Dermatophytosis Drugs Sales Forecast by Product 2019-2025
  • 12.2.2 Global Dermatophytosis Drugs Revenue Forecast by Product 2019-2025
• 12.3 Dermatophytosis Drugs Market Forecast by End User
• 12.4 North America Dermatophytosis Drugs Forecast
• 12.5 Europe Dermatophytosis Drugs Forecast
• 12.6 Asia Pacific Dermatophytosis Drugs Forecast
• 12.7 Central & South America Dermatophytosis Drugs Forecast
• 12.8 Middle East and Africa Dermatophytosis Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Dermatophytosis Drugs Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Ringworm on the skin like athlete's foot (tinea pedis) and jock itch (tinea cruris) can usually be treated with non-prescription antifungal creams, lotions, or powders applied to the skin for 2 to 4 weeks.
The global Dermatophytosis Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Dermatophytosis Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Dermatophytosis Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Dermatophytosis Drugs in these regions.
This research report categorizes the global Dermatophytosis Drugs market by top players/brands, region, type and end user. This report also studies the global Dermatophytosis Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Novartis
Pfizer
Sanofi-Aventis
Merck
Enzon Pharmaceuticals
Bayer
Astellas Pharma
GSK
Abbott

Market size by Product
Rx
OTC
Market size by End User
Hospital
Clinic
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Dermatophytosis Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Dermatophytosis Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Dermatophytosis Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Dermatophytosis Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Dermatophytosis Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Dermatophytosis Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.